Browsing Tag
clinical trials
131 posts
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted…
September 20, 2024
Longboard Pharmaceuticals shares see spike as FDA recognizes potential of bexicaserin in Dravet syndrome
Shares of Longboard Pharmaceuticals, Inc. surged on Thursday after the United States Food and Drug Administration (FDA) granted…
September 19, 2024
Actinogen Medical makes bold A$11.1m move to boost Alzheimer’s drug trial
Actinogen Medical has raised 11.1 million AUD in a significant capital raise led by its CEO, Dr. Steven…
September 18, 2024
Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data…
September 11, 2024
Shockwave through biotech: AN2 Therapeutics slashes workforce after trial fails
AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its…
August 10, 2024
Is the cure for PTSD waiting in the wings? FDA says not yet!
In a significant regulatory decision, the U.S. Food and Drug Administration (FDA) has decided not to approve the…
August 10, 2024
HCLTech launches advanced clinical trials solution with Denodo and AWS
HCLTech, a prominent global technology company, has unveiled a cutting-edge clinical trials and diagnosis solution developed in collaboration…
August 6, 2024
FDA committee endorses Zevra Therapeutics’ arimoclomol as a treatment for Niemann-Pick Disease Type C
In a notable advancement for rare disease treatment, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has received a significant endorsement…
August 3, 2024
$35 million boost for Rona Therapeutics: A new era in RNA medicine begins!
Rona Therapeutics, a clinical-stage company leading the way in nucleic acid drug research and development, has successfully completed…
July 20, 2024
Exscientia takes full ownership of cdk7 inhibitor in oncology breakthrough
Exscientia plc (Nasdaq: EXAI), a pioneer in AI-driven drug discovery, has reached a strategic milestone by acquiring full…
July 20, 2024